expos enbrel risk
maintain market perform rate share
follow review result result
better-than-expect support broad-bas product
perform believ share fairly-valu growth
would take wait-and-se approach pend resolut enbrel
report result yesterday market
close provid updat key oper pipelin
strateg initi non-gaap ep slightli ahead
consensu total revenu vs consensu
updat ep guidanc
increas revenu guidanc
prior guidanc total net sale
decreas year-over-year consensu sale
consensu xgeva vs consensu
aimovig vs consensu in-lin sale kyproli
vs consensu consensu sale
vs consensu due increas biosimilar competit
repatha vs consensu non-
gaap ep vs prior
focu key trend assumpt note sale
declin volum growth newer product slightli outpac
declin matur product invest pipelin new
product growth sg increas increas year-
year yoy driven primarili increas spend research
earli oncolog pipelin off-set partial decreas spend
support market product overal non-gaap oper incom
declin yoy free cash flow saw declin driven
primarili advanc tax deposit payment reduc price
repatha avail medicar patient
access continu expect impact enbrel
beat driven increas volum secondari lower price
paribiv uptak continu outperform xgeva uptak
continu benefit label expans myeloma amgn
recent launch bone franchis product even perform well
japan aimovig remain lead cgrp
continu page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
non-gaap ep exclud stock-bas compens reflect adjust
compani data secur llc estim reuter
amgn updat includ posit comment kra inhibitor includ recist respons
colorect cancer respons appendic cancer nsclc enrol patient pd-
combin trial later open phase monotherapi nsclc cohort may
support approv expect move baff-ico bispecif peptid
sirna phase trial system lupu erythematosu cv diseas increas lp
focu biosimilar expect approv present kanjinti hercetpin
bsufa abp remicad bsufa phase data abp rituxan
note increas confid long act bite molecul paus develop
car-t product note hle-bit
price target nc
arriv price target appli multipl ep estim risk includ
greater expect eros base biolog busi competit kyproli gener
velcad emerg myeloma treatment failur gain approv proprietari biosimilar
expens price-to-earnings basi rel growth view face signific headwind
biosimilar brand competit legaci franchis
larg cap global commercial-stag biotechnolog compani discov develop biolog
small molecul drug specialti physician discoveri pipelin led compani
broaden focu oncolog immune-medi inflammatori diseas renal diseas includ
bone diseas cardiovascular neurolog diseas addit taken lead posit
develop biosimilar compani face near-term biosimilar competit legaci
